Aquestive Therapeutics, Inc. stock is up 52.5% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 5 December’s closed higher than November. 100% of analysts rate it a buy.
Aquestive Therapeutics, Inc. focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formant of buprenorphine and naloxone for the. treatment of opioid dependence.